BioCentury
ARTICLE | Regulation

Roche building bispecific franchise outside oncology with Vabysmo approval

Ophthalmic bispecific Vabysmo reaches crowded AMD, DME market with blockbuster potential

February 1, 2022 2:10 AM UTC

Roche adds a second non-oncology bispecific with blockbuster potential to its product portfolio with the approval of Vabysmo, further proof that bispecific antibodies are set to make an impact on drug ...



Access this Article